Orexo AB to Acquire Biolipox AB - Building a Specialty Pharma Company Driven by Innovation; SEK 856 Million
10/15/2007 12:41:44 PM
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo AB (STO:ORX) and the principal owners of Biolipox AB have reached an agreement under which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
The acquisition will create an innovative specialty pharma company with a broad product pipeline, global partnerships with major financial potential, and established sales channels. Substantial shareholder value will be created through operational synergies and by optimizing the potential of the combined product pipeline.
comments powered by